Aristides Capital’s Lexeo Therapeutics LXEO Stock Holding History

Aristides Capital’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,285	Closed	-$193K	–	289
2024 Q4	$193K	Buy	+29,285	New	+$231K	0.04%	249

Other funds holding LXEO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Aristides Capital's LXEO Position: Q1 2025 in Review

Aristides Capital sold out of Lexeo Therapeutics (LXEO) in Q1 2025, closing a stake of 29,285 shares — an estimated $193K sold.

Aristides Capital first reported a position in LXEO in Q4 2024 and held it in 1 quarter. The position peaked at $193K in Q4 2024. 88 funds tracked by Wall St. Rank hold LXEO as of Q1 2025.

Aristides Capital reported no remaining Lexeo Therapeutics position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 29,285 Lexeo Therapeutics shares in Q1 2025, an estimated $193K.
Aristides Capital first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 1 quarter.
Aristides Capital's Lexeo Therapeutics position peaked at $193K in Q4 2024.
88 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.